Patents by Inventor Charles W. Johannes

Charles W. Johannes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT
    Publication number: 20230083431
    Abstract: The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.
    Type: Application
    Filed: December 15, 2020
    Publication date: March 16, 2023
    Applicants: Merck Sharp & Dohme LLC, MSD International GMBH (Singapore Branch), Agency for Science, Technology and Research
    Inventors: Nicolas C. Boyer, Michael B. Garrigou, Sookhee Nicole Ha, Chunhui Huang, Anthony W. Partridge, Tomi K. Sawyer, Pietro Aronica, Charles W. Johannes, Srinivasaraghavan Kannan, Chandra S. Verma, Tsz Ying Yuen
  • P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES
    Publication number: 20220267376
    Abstract: Peptidomimetic macrocycles that comprise all-D configuration ?-amino acids and bind mouse double minute 2 (MDM2 aka E3 ubiquitin-protein ligase) and MDMX (aka MDM4) are described. These all-D configuration ?-amino acid peptidomimetic macrocycles are protease resistant, cell permeable without inducing membrane disruption, and intracellularly activate p53 by binding MDM2 and MDMX thereby antagonizing MDM2 and MDMX binding to p53. These peptidomimetic macrocycles may be useful in anticancer therapies, particularly in combination with chemotherapy or radiation therapy.
    Type: Application
    Filed: June 16, 2020
    Publication date: August 25, 2022
    Applicants: Merck Sharp & Dohme Corp., Agency for Science, Technology and Research, MSD International GMBH (Singapore Branch)
    Inventors: Pietro Aronica, Christopher J. Brown, Fernando J. Ferrer, Charles W. Johannes, Srinivasaraghavan Kannan, David P. Lane, Anthony W. Partridge, Tomi K. Sawyer, Yaw Sing Tan, Chandra S. Verma, Tsz Ying Yuen
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 9879293
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 30, 2018
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • PHOSPHORUS-CONTAINING CATALYSTS
    Publication number: 20170282170
    Abstract: The invention provides compounds of general structure I: (Ar1—Ar2—Ar3-E-P(=D)R2-)nMmXnLn?.
    Type: Application
    Filed: August 29, 2014
    Publication date: October 5, 2017
    Applicant: Agency for Science, Technology and Research
    Inventors: Charles W. Johannes, Edward G. Robins, Howard Jong, Yee Hwee Lim, Saei Weng Chia, Yong Yang, Anil Podichetty
  • PHOSPHORUS-CONTAINING CATALYSTS
    Publication number: 20160207034
    Abstract: The invention provides compounds of general structure I: (Ar1—Ar2—Ar3-E-P(=D)R2-)nMmXnLn?.
    Type: Application
    Filed: August 29, 2014
    Publication date: July 21, 2016
    Applicant: Agency for Science, Technology and Research
    Inventors: Charles W. Johannes, Edward G. Robins, Howard Jong, Yee Hwee Lim, Saei Weng Chia, Yong Yang, Anil Podichetty
  • ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
    Publication number: 20160177354
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 23, 2016
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20140371456
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: April 21, 2014
    Publication date: December 18, 2014
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Sheldon L. Wallerstein, Gregg F. Keaney, Priscilla L. White, Charles W. Johannes
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 8703448
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 22, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8609706
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: December 17, 2013
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20130131063
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: May 15, 2012
    Publication date: May 23, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8178690
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 15, 2012
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence Blas Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Enzymatic Transamination of Cyclopamine Analogs
    Publication number: 20120083607
    Abstract: Provided are processes for the synthesis of amino analogues from ketone starting materials.
    Type: Application
    Filed: July 1, 2011
    Publication date: April 5, 2012
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Brian c. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners
    Publication number: 20110213145
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Application
    Filed: April 19, 2011
    Publication date: September 1, 2011
    Applicant: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 7928244
    Abstract: The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: August 21, 2007
    Date of Patent: April 19, 2011
    Assignee: Infinity Discovery, Inc.
    Inventors: Alfredo C. Castro, Kristopher M. Depew, Michael J. Grogan, Charles W. Johannes, Edward B. Holson, Brian T. Hopkins, Gregg F. Keaney, Nii O. Koney, Tao Liu, David A. Mann, Marta Nevalainen, Stephane Peluso, Lawrence B. Perez, Daniel A. Snyder, Thomas T. Tibbitts